India’s Dr Reddy’s has expanded its Custom Pharmaceutical Services business in the UK by opening a new, purpose-built Technology Centre for its Chirotech subsidiary on the Cambridge Science Park, where Chirotech has been based for the last 20 years.
Dr Reddy’s acquired Chirotech from Dow Chemical in 2008. The new 33,000sq ft facility, which Dr Reddy’s says will contribute to doubling its scientific staff in Cambridge, with capacity for further expansion in the future, has been fitted to the parent company’s specifications for chemistry, biology and analytics.
The additional capacity will help to strengthen Chirotech’s core capabilities in
biocatalysis and chemocatalysis, as well as building resources for fast-growing segments such as activated mPEGs (used for pegylation of biologic drugs and, increasingly, of peptides and small-molecule pharmaceuticals) and peptides, and enabling development of other areas of expertise in chemistry and processing for use in the pharmaceutical industry, Dr Reddy’s said.
“The facility will be a centre of excellence for chemistry and reinforces our commitment to building a leading edge research organisation to meet the innovation needs of our customers,” commented vice-chairman and chief executive officer G V Prasad.
